Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity

• প্রধান লেখক: Xinghua Pang (লেখক), Zhaoliang Huang (লেখক), Tingting Zhong (লেখক), Peng Zhang (লেখক), Zhongmin Maxwell Wang (লেখক), Michelle Xia (লেখক), Baiyong Li (লেখক)
• বিন্যাস: গ্রন্থ
• প্রকাশিত: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• বিষয়গুলি: article
• অনলাইন ব্যবহার করুন: Connect to this object online.

ABSTRACTClinical studies have shown that combination therapy of antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) significantly improves clinical benefit over PD-1 antibody alone. However, broad application of this combination has been limited by toxic...